Calendario›REGN›REGN5713

REGN5713

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Ensayo de REGENERON PHARMACEUTICALS, INC. en Conjuntivitis alergica.

Más ensayos de: Conjuntivitis alérgica.

Fase

Fase 3

Estado

Completado

Participantes

54

previstos

Centros

3

Fin del objetivo primario

abr 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2024.

Qué mide

Ocular itch score in response to birch allergen challenge (At Day 8 post-Conjunctival Allergen Challenge (CAC)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06602739), actualizada en abr 2026.